Francisco Silva

prnewswire.com/news-releases/… @exosome

The last patient has been dosed in $BRTX's fully enrolled Phase 2 clinical trial evaluating BRTX-100 for the treatment of cLDD, completing treatment administration of its lead clinical program & advancing the study into the next blinded follow-up stage. 🔗 bit.ly/4dxJoMf

$BRTX announces expanded blinded data from its fully enrolled Phase 2 clinical trial evaluating BRTX-100, showing sustained improvements in both pain and function among patients with CLDD. Learn more about the data presented at @ISCTglobal: bit.ly/4no20l6 #ISCT2026

Don’t miss $BRTX's presentations at @ISCTglobal! Our team will share the latest safety and blinded efficacy data from our fully enrolled, ongoing Phase 2 study in chronic lumbar disc disease and preclinical data on our therapeutic and biocosmeceutical exosome platform. #ISCT2026

$BRTX's CEO, Lance Alstodt, shared progress on our lead cell therapy candidate, BRTX-100, the regulatory and manufacturing landscape for autologous therapies, and the potential for regenerative platforms to reshape treatment approaches. Read more here: drug-dev.com/expert-content…

#brtx #biorestorative

Biologic for potential long-term space exploration and travel. Stacking inventions!!! #mitochondria #stemcells #regenerativemedicine #brownfat #aging #mesenchymal

This review explores the impact of hypoxic preconditioning on umbilical cord-MSCs, with a focus on how reduced oxygen levels influence their biological traits and enhance their therapeutic potential. 🧫💊 📚 bit.ly/4mgUHLq

$BRTX announced a strategic collaboration with 203 Creates, a Stamford, CT-based firm specializing in the development, marketing, and growth of luxury, premium, and science-backed brands to advance BioRestorative’s #biocosmeceutical platform. Read more: bit.ly/4bWSC3Q

$BRTX announces new, blinded data on ~45 patients from its Phase 2 trial evaluating hypoxic-cultured mesenchymal stem cells for the treatment of chronic lumbar disc disease that will be presented at the @ORSsociety Meeting. Read more: ir.biorestorative.com/news-events/pr… #ORS2026

Over 25 million Americans live with chronic lower back pain each year and traditional treatments aren’t cutting it. BRTX-100 was invented to combat this pain using single-injection therapy. Learn more: biorestorative.com/brtx-100-2/ #BioRestorativeTherapies $BRTX @elonmusk

BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium globenewswire.com/news-release/2…

$brtx expanding its ability to manufacture and distribute off-the-shelf therapies. We have been building a path towards commercialization. - Orthobiologics Phase 2 clinical trial - Strong IP portfolio - Commercial cosmetic pipeline - Expanding into off-the-shelf-therapies

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health $BRTX healthstockshub.com/news/nasdaq/br…

@exosome I believe so I haven’t seen him in a while.

@fj74582 My man !!! is Warren still in NYC?

I miss Alan Lewis....

nejm.org/doi/full/10.10… Big things are coming. #brownfat #mitochondria #thermostem

@exosome Congrats Tim and Pete! Get it!

Proud to ring the NASDAQ opening bell with $fblg Fibrobiologics

Just finished up #ors2024 great conference and opportunity to provide an update on our clinical developments. Lots of developments for 2024. #data #brtx100 #catalystrichyear #midastouch #winning